Two of the pharmaceutical and healthcare sector’s biggest names are weighing structural changes that could reshape how medicines are priced and distributed across the industry.
CVS Health, one of the largest integrated pharmacy and insurance businesses in the United States, is preparing to divide itself into two separate companies.
The planned break-up marks a significant strategic reversal for a corporation that spent years building a vertically integrated model spanning retail pharmacy, pharmacy benefit management, and health insurance.
Integrated healthcare conglomerates have faced sustained pressure from investors, regulators, and policymakers who argue that combining those functions concentrates too much market power in a single organisation.
A split would allow each resulting business to focus on its own operations, capital allocation priorities, and competitive positioning without the complexity of managing fundamentally different business lines.
Separately, German pharmaceutical giant Bayer is reported to be weighing whether to adopt a Most Favoured Nation pricing approach for its drug portfolio.
MFN pricing mechanisms tie what a country or payer is charged to the lowest price offered to any other buyer globally, a model that has attracted significant political attention in markets where drug costs are a persistent concern.
For Bayer, the consideration signals growing pressure on large pharmaceutical manufacturers to demonstrate pricing restraint amid intensifying scrutiny from governments and insurers alike.
The timing of both developments reflects a broader moment of reckoning across the healthcare industry, where scale that was once considered a competitive advantage is increasingly being questioned.
Whether CVS Health can execute a clean corporate separation while maintaining continuity for millions of pharmacy and insurance customers will be among the most closely watched business stories of the coming months.
Bayer’s MFN deliberations, meanwhile, could influence how other multinational drug companies respond to political demands for pricing transparency and fairness in major markets.
Both stories underscore how external pressure, whether from capital markets, regulators, or policymakers, is now driving structural decisions that company executives might previously have resisted.